China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
CompanyDrug

China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain
CompanyDeals

Sun-Novo Pharma Collaborates with LeKuang Huilin on STC007 for Post-Abdominal Surgery Pain

AbbVie's Venclexta Approved by China's NMPA for CLL/SLL Patients with 17p Deletion
CompanyDrug

AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion

Changchun GeneScience's Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
CompanyDrug

Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics
CompanyDeals

XtalPi Completes Pre-Seed Investment in Foundry BioSciences to Advance AI-Driven Longevity Therapeutics

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
CompanyDrug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3
CompanyDrug

InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors
CompanyDrug

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC
CompanyDrug

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC

Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
CompanyDrug

Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency

3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions
CompanyDeals

3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions

Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73
CompanyDrug

Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73